25 May 2013
Keywords: strong, ph, iii, data, titan, addiction, implant
Article | 01 December 2008
The USA's Titan Pharmaceuticals reported positive data from a Phase III study of Probuphine, a subcutaneous implant designed to deliver ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
4 August 2008
24 May 2013
© 2013 thepharmaletter.com